| Unique ID issued by UMIN | UMIN000060176 |
|---|---|
| Receipt number | R000068822 |
| Scientific Title | A Study on the Efficacy and Safety of Minocycline and Sitafloxacin for Non-gonococcal Urethritis in Men |
| Date of disclosure of the study information | 2025/12/23 |
| Last modified on | 2025/12/23 11:26:49 |
A Study on the Efficacy and Safety of Minocycline and Sitafloxacin for Non-gonococcal Urethritis in Men
A Study on the Efficacy and Safety of Minocycline and Sitafloxacin for Non-gonococcal Urethritis in Men
A Study on the Efficacy and Safety of Minocycline and Sitafloxacin for Non-gonococcal Urethritis in Men
A Study on the Efficacy and Safety of Minocycline and Sitafloxacin for Non-gonococcal Urethritis in Men
| Japan |
Non-gonococcal Urethritis
| Urology |
Others
NO
A Study on the Efficacy and Safety of Minocycline and Sitafloxacin for Non-gonococcal Urethritis in Men
Safety,Efficacy
Efficacy and Safety 21 to 28 Days After Initiation of Minocycline Treatment
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Medicine |
Patients with non-gonococcal urethritis should receive minocycline 100 mg orally twice daily for 7 days. If testing at the start of minocycline therapy is positive for M. genitalium, sitafloxacin 100 mg should be added orally twice daily for an additional 7 days.
| 16 | years-old | <= |
| Not applicable |
Male
Symptoms: Patients presenting with symptoms of non-gonococcal urethritis.
Pyuria: Cases meeting any of the following criteria for pyuria prior to initiation of medication.
Using non-centrifuged urine with a designated device: >=10 WBCs/uL
Using non-centrifuged urine with a urine test strip method (based on esterase activity measurement): Positive
Urinalysis sediment microscopy: >=5 WBCs/hpf
1) Patients who received other antimicrobial agents prior to study drug initiation and whose symptoms were already improving
2) Patients who received tetracycline-class antimicrobial agents within one week prior to study drug initiation
3) Patients with severe underlying diseases or complications that would make it difficult to evaluate the efficacy and safety of the study drug
4) Patients with a history of allergy to tetracycline-class antimicrobial agents
5) Patients with severe cardiac dysfunction or hepatic dysfunction
6) Patients with moderate or greater renal impairment (serum creatinine >= 2 mg/dL as a guideline)
7) Other patients deemed unsuitable by the attending physician
100
| 1st name | Mitsuru |
| Middle name | |
| Last name | Yasuda |
Sapporo Medical University School of Medicine
Department of Infection Control & Laboratory Medicine
060-8543
S1 W16,Chuo-ku,Sapporo,060-8543,JAPAN
+81-11-611-2111
yasuda7jpe@sapmed.ac.jp
| 1st name | Mitsuru |
| Middle name | |
| Last name | Yasuda |
Sapporo Medical University School of Medicine
Department of Infection Control & Laboratory Medicine
060-8543
S1 W16,Chuo-ku,Sapporo,060-8543,JAPAN
+81-11-611-2111
yasuda7jpe@sapmed.ac.jp
Sapporo Medical University School of Medicine
Japan Agency for Medical Research and Development
Japanese Governmental office
Sapporo Medical University Hospital Institutional Review Board
S1 W16,Chuo-ku,Sapporo,060-8543,JAPAN
+81-11-611-2111
ji-rskk@ml.sapmed.ac.jp
NO
| 2025 | Year | 12 | Month | 23 | Day |
Unpublished
Open public recruiting
| 2023 | Year | 05 | Month | 22 | Day |
| 2024 | Year | 01 | Month | 11 | Day |
| 2024 | Year | 01 | Month | 11 | Day |
| 2027 | Year | 03 | Month | 31 | Day |
| 2025 | Year | 12 | Month | 23 | Day |
| 2025 | Year | 12 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068822